Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127790511 | 12779051 | 1 | I | 2016 | 20160617 | 20160926 | 20160926 | PER | US-JAZZ-2016-US-011458 | JAZZ | 36.93 | YR | M | Y | 104.31000 | KG | 20160926 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127790511 | 12779051 | 1 | PS | XYREM | SODIUM OXYBATE | 1 | Oral | 2.25 G, BID | 21196 | 2.25 | G | ORAL SOLUTION | |||||||
| 127790511 | 12779051 | 2 | SS | XYREM | SODIUM OXYBATE | 1 | Oral | DOSE ADJUSTMENTS | 21196 | ORAL SOLUTION | |||||||||
| 127790511 | 12779051 | 3 | SS | XYREM | SODIUM OXYBATE | 1 | Oral | 4.5 G, BID | 21196 | 4.5 | G | ORAL SOLUTION | |||||||
| 127790511 | 12779051 | 4 | SS | LITHIUM. | LITHIUM | 1 | UNK | N | 0 | ||||||||||
| 127790511 | 12779051 | 5 | C | ADDERALL | AMPHETAMINE ASPARTATEAMPHETAMINE SULFATEDEXTROAMPHETAMINE SACCHARATEDEXTROAMPHETAMINE SULFATE | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 6 | C | PRISTIQ EXTENDED-RELEASE | DESVENLAFAXINE SUCCINATE | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 7 | C | NUVIGIL | ARMODAFINIL | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 8 | C | ALEVE | NAPROXEN SODIUM | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 9 | C | ASPIRIN. | ASPIRIN | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 10 | C | IBUPROFEN. | IBUPROFEN | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 11 | C | LAMICTAL | LAMOTRIGINE | 1 | U | 0 | |||||||||||
| 127790511 | 12779051 | 12 | C | XANAX | ALPRAZOLAM | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127790511 | 12779051 | 1 | Narcolepsy |
| 127790511 | 12779051 | 2 | Somnolence |
| 127790511 | 12779051 | 4 | Affective disorder |
| 127790511 | 12779051 | 5 | Attention deficit/hyperactivity disorder |
| 127790511 | 12779051 | 6 | Depression |
| 127790511 | 12779051 | 7 | Somnolence |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127790511 | 12779051 | Dizziness | |
| 127790511 | 12779051 | Emotional disorder | |
| 127790511 | 12779051 | Fatigue | |
| 127790511 | 12779051 | Feeling drunk | |
| 127790511 | 12779051 | Nausea | |
| 127790511 | 12779051 | Night sweats | |
| 127790511 | 12779051 | Somnolence | |
| 127790511 | 12779051 | Wrong technique in product usage process |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127790511 | 12779051 | 1 | 201604 | 201604 | 0 | |
| 127790511 | 12779051 | 2 | 201604 | 201605 | 0 | |
| 127790511 | 12779051 | 3 | 201605 | 0 | ||
| 127790511 | 12779051 | 4 | 20160718 | 0 |